http://www.regentherapeutics.com/regen

Consider a company with a market cap of around 10 million which could well in the future be generating revenue well in excess of that figure every year. Interested then read on and DYOR on Regen Therapeutics.

For some time now I have been a shareholder of RGT who have been working with a patented product Colostrinin as a treatment for Alzheimers. Tests so far would seem to indicate that it is a success and they are currently refining a pharmaceutical product.

Meantime they are also pushing forward on the nutraceutical front as tests have shown positive results in respect of mild cognitive disorders (memory loss etc). Further research is being carried out regarding other major illnesses. As at mid 2007 a launch is scheduled in the US for Q4 and there are rumours of an earlier launch in Australia possibly imminent based on the fact that adverts are already starting to appear see:- http://www.quantumevolution.com.au/oscommerce/index.php

They have also acquired a contract research organisation which should mean that research money for clinical trials that had previously been spent will now be kept inside the group.

February 2006 has seen Regen acquire the rights, following a feasibility study, in respect of other uses for a well known drug (Zolpidem) that has undergone phase 2 clinical trials where results are expected around August 2007. The new use relates to the positive effects that have been seen when treating stroke victims with the drug. There has been a lot of press interest which a web search should reveal.

An interview with the chairman (Percy Lomax) in the summer of 2004 talked of a nutraceutical product producing royalty payments of 10% on a possible 100 million sales per annum. The pharmaceutical version which also requires a licensing partner will if successful have projected sales of 1-5 billion again which would generate royalty payments to Regen. I leave you to contemplate just how high the share price would be if this were the case but suffice to say it will be many many times what it is now.

Acquisition (Oct 2004) of Guildford Clinical Pharmacology unit demonstrates not only that they are progressive and expanding but also thinking strategically for GCPUL being a research based company no doubt Regen can now keep such costs within the group whereas before testing had to be paid for elsewhere. This acquisition also means that they have revenue and are therefore no longer a "virtual" company.

A share issue in July 2007 means that they should now have funds in hand to take them through to cash generation. Hopefully this means we have seen the last of the issues excepting any used by way of acquiring profitable companies.

The North America link is an interesting one as perhaps in readiness for the launch of Colostrinin out there Regen set up an ADR programme which became effective in March 2005. ADR's ( American Depositary Receipts) are a way for US investors to buy shares in UK companies. In Regen's case one ADR is equivalent to 200 Regen UK shares so when an ADR is purhased the Bank of New York will buy the proportionate number of UK shares and convert them into ADR's for the investor. At present this is not a factor however with the launch of Colostrinin out there if successful it may mean that US investors will want to be involved in the company and that will have a direct positive impact on our share price. In the US Colostrum (from which Colostrinin is produced )is already a recognised and popular health product and so demand should be good.

So all in all exciting times ahead. There can be few shares around that offer the potential of this one although as always DYOR and good luck with your investments whatever you decide here.

From Sunday Telegraph (www.telegraph.co.uk/news) search under ReGen for this article:-

'Hello mum. Am I in hospital?'
By Olga Craig
(Filed: 28/05/2006)

It is copyrighted so I cannot post it here. Worth a read for anyone who has not seen it. It expands ReGen's RNS of 22 May a bit, also mentions ReGen's trials with Zolpidem.
kim

Hi all

Huge PR coverage of Zolpidem over the weekend including the whole of page 3 of the Times on Saturday.

Nature: 23 May 2006

http://www.nature.com/news/2006/060522/full/060522-9.html

The Guardian: 23 May 2006

http://browse.guardian.co.uk/search?search=zolpidem

The Times: 27 May 2006

http://www.timesonline.co.uk/article/0,,2-2199122.html

Sunday Telegraph: 28 May 2006

http://www.telegraph.co.uk/news/main.jhtml?xml=/news/2006/05/28/npvs28.xml

Finally Regen get their PR together - could be a promising week ahead.

SP back down again, even after so much positive information about Zolpidem. I have to say that I'm struggling to understand the market's reaction to RGT.

What's it going to take to make these take off? Anyone?

Queen1, patience is required if you are going to reap the fruits of this little beauty! They are not far away from a breakthrough and a deal of some sort is also in the offing, though I am not sure how lucrative it will be but, as with any share of this type, a helping hand is needed and a bigger named pharma taking an interest will inevitably put a rocket under the share price. A year in a company like this is equivalent to a week in a company like, say, GlaxoSmithkline, if you get my meaning. A few years ago I would have said "good luck with your investment" now, I genuinely believe that luck no longer plays a part; they are on to something big. But as always, DYOR!!
kim

Hi Kim

Thanks for that. I've been a holder for 18 months now so I must have at least a modicum of patience!

Well done Queen1! I am sure your patience will be rewarded....in time!
kim

In the Daily Express today:

"Share Whisper

Shares in ReGen Therapeutics climbed 0.05p to 1.2p on suggestions the company was close to announcing a tie-up with a major US company.
Traders are also hoping for a positive update later this year with a clinical study in South Africa on a new use for its insomnia treatment zolpidem."

Thanks Dinky1, it will be good to see ReGen move into the big time, it is long overdue.
kim

Completely agree.
I don't usually post here, so sorry for intruding.
I am a long term holder who tends to post elsewhere....but I believe that Gantenbrink is away, so I thought i'd pop over here and post the news.
Good luck everyone! Hopefully our patience will soon be rewarded.

Not taken as an intrusion Dinky1, good to see you here, it is a much quiter thread than the other, perhaps we should have CB here for a while!!
kim

Response to press comment

RNS Number:6210F
ReGen Therapeutics PLC
04 July 2006

For immediate release

ReGen Therapeutics Plc

4 July 2006

Statement in response to press comment

ReGen Therapeutics Plc ("ReGen") announces that in the light of recent press
comment it is in discussions regarding a licensing agreement for the commercialization of ColostrininTM in North America. These discussions have been
in progress for some time.

A further announcement will be made when appropriate.

Another "buy on rumour, sell on fact" rise.

Possibly Keaydian, but I think that the sp is more likely to hold should the license agreement prove positive, also they have a very good chance of making the big time in a spectacular fashion if the zolpidem drug is marketed as one that can reverse severe brain damage. The results from studies so far are incredible.
kim

Hi guys. Thanks for posting the info Dinky1. I do not visit here as often as I ought, considering I started the thread but I tend to get caught up across the way so by all means post any news as it's good to see contribution and general activity here.

Anyway nice to see our patience being rewarded and Regen finally starting to be recognised.

Other news is that a Regen interview will apparently appear on ABC's Good Morning America tomorrow between 7 - 9am focussing on Zolpidem. It will be interesting to see how the US reacts. The markets have been closed there today. Tomorrow they'll hear about what the UK press described a s a "miracle" drug just a couple of weeks ago. Then on investigation they'll find that Regen are rumoured to be doing a deal on another product with a large company in their own country and then they'll see a share price that appears to be lifting off. If Pali Capital can get their act together and start shifting those ADRs (which equate to 200 UK shares) then US buyng could have a significant effect on our market.

Hopefully this is just the beginning. News of a deal should move us up further and then with Zolpidem and CLN pharma following behind the sky's the limit.

Good luck all

Welcome back Gantenbrink. With Discovery now in orbit and ReGen rocketing, it may be time for celebration?!
kim

Interesting times indeed chaps. Onwards and upwards!

This share is so frustrating! Down again and for no reason!!!

i take it everything we read on ADVFN is to be taken with a pinch of salt?? from being hugely bullish they have IMO turned somewhat bearish. I am not selling this till at least 5p where i will re assess the situation.

License agreement announced today with US neutraceutical developer, Metagenics, to commercialise Colostrinin.